Irritable Bowel Syndrome With Constipation (IBS-C) Clinical Trial
Official title:
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old
Verified date | April 2024 |
Source | Ardelyx |
Contact | Jocelyn Tabora |
Phone | 510-745-1724 |
jtabora[@]ardelyx.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 17 Years |
Eligibility | Inclusion Criteria: - =12 and <18 years old - Patient weighs =18 kg at the time the patient provides written assent - Females of child-bearing potential must have negative pregnancy test at Visit 1 (serum) and Visit 2 (urine) and confirm the use of appropriate contraception (including abstinence). - Patient meets the Rome IV criteria for child/adolescent diagnosis of IBS-C - Patient is willing to discontinue any laxatives used in favor of the protocol-permitted rescue medicine (which will only be allowed after 72 hours with no bowel movement) - Patient meets the entry criteria assessed during the 2-week Screening period. - Ability of both the patient and parent/guardian/LAR to communicate with the Investigator and to comply with the requirements of the entire study, including an understanding of the assessments in the eDiary and how to use the eDiary device - Patient must provide written assent and the parent/guardian/LAR must provide written informed consent before the initiation of any study-specific procedures Exclusion Criteria: - Functional diarrhea as defined by Rome IV child/adolescent criteria - IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome IV child/adolescent criteria - History of non-retentive fecal incontinence. - Required manual disimpaction any time prior to randomization (after consent); - Has both unexplained and clinically significant alarm symptoms (lower gastrointestinal [GI] bleeding [rectal bleeding or heme-positive stool], iron-deficiency anemia, or any unexplained anemia, or weight loss) and systemic signs of infection or colitis, or any neoplastic process - Patient has any of the following conditions: - Celiac disease, or positive serological test for celiac disease - Cystic fibrosis - Hypothyroidism that is untreated or treated with thyroid hormone - Down's syndrome or any other chromosomal disorder - Active anal fissure - Anatomic malformations (eg, imperforate anus) - Intestinal nerve or muscle disorders (eg, Hirschprung disease) - Neuropathic conditions (eg, spinal cord abnormalities) - Lead toxicity, hypercalcemia - Neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary (Electronic handheld device) - Inflammatory bowel disease - Childhood functional abdominal pain syndrome - Childhood functional abdominal pain; - Poorly treated or poorly controlled psychiatric disorders that might influence his or her ability to participate in the study; - Lactose intolerance that is associated with abdominal pain or discomfort - History of cancer other than treated basal cell carcinoma of the skin; (Note: Patients with a history of cancer are allowed provided that the malignancy has been in a complete remission for at least 5 years before the Randomization Visit.) - History of diabetic neuropathy. - Use of medications that are known to affect stool consistency (Prohibited Medications), including fiber supplements, anti-diarrheals, cathartics, antacids, opiates, prokinetic drugs, laxatives, enemas, antibiotics during the Screening period; unless specified as rescue medication, and used accordingly as directed by the Investigator. - Patient has had surgery that meets any of the following criteria: - Bariatric surgery for treatment of obesity, or surgery to remove a segment of the GI tract at any time before the Screening Visit; - Surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the Screening Visit; - An appendectomy or cholecystectomy during the 60 days before the Screening Visit; - Other major surgery during the 30 days before the Screening Visit - History of alcohol or substance abuse - Participation in other clinical trials within 1 month prior to Screening - Patient and/or parent/guardian/LAR is involved in the conduct and/or administration of this trial as an investigator, sub-investigator, trial coordinator, or other staff member, or the patient is a first-degree family member, significant other, or relative residing with one of the above persons involved in the trial - If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition, which would render the results uninterpretable |
Country | Name | City | State |
---|---|---|---|
United States | Advanced Research Center, Inc. | Anaheim | California |
United States | Boys Town National Research Hospital | Boys Town | Nebraska |
United States | Advantage Clinical Trials | Bronx | New York |
United States | SUNY Downstate Medical Center | Brooklyn | New York |
United States | Atrium Health | Charlotte | North Carolina |
United States | Prohealth Research Center | Doral | Florida |
United States | Velocity Clinical Research, Providence | East Greenwich | Rhode Island |
United States | G & L Research, LLC | Foley | Alabama |
United States | Prisma Health Children's Hospital | Greenville | South Carolina |
United States | Texas Digestive Specialists | Harlingen | Texas |
United States | Med Clinical Research Partners, LLC | Irvington | New Jersey |
United States | Frontier Clinical Research | Kingwood | West Virginia |
United States | I.H.S. Health, LLC | Kissimmee | Florida |
United States | Valencia Medical and Research Center | Miami | Florida |
United States | AIM Trials, LLC | Plano | Texas |
United States | M3 Wake Research, Inc | Raleigh | North Carolina |
United States | Sun Research Institute | San Antonio | Texas |
United States | Frontier Clinical Research, LLC | Scottdale | Pennsylvania |
United States | Frontier Clinical Research, LLC | Smithfield | Pennsylvania |
United States | Florida Pharmaceutical Research and Associates, Inc. | South Miami | Florida |
United States | Pioneer Research Solutions Inc | Sugar Land | Texas |
United States | Eclipse Clinical Research | Tucson | Arizona |
United States | ClinPoint Trials | Waxahachie | Texas |
Lead Sponsor | Collaborator |
---|---|
Ardelyx |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6/12-week APS (abdominal pain and SBM) +2 response | 6/12-week APS (abdominal pain and SBM (spontaneous bowel movement)) +2 response, defined as achieving the weekly APS +2 response criteria (i.e., achieving both weekly SBM +2 response and weekly abdominal pain response during the same week) for =6 out of the 12 weeks of the RTP.
The weekly SBM +2 response is defined as having an increase of =2 from baseline in the average weekly SBM frequency for a given week The weekly abdominal pain response is defined as having =30% reduction from baseline in the average weekly abdominal pain score for a given week |
12 weeks | |
Secondary | 6/12-week SBM +2 response | 6/12-week SBM +2 response: defined as achieving the weekly SBM +2 response for =6 out of the 12 weeks of the RTP | 12 weeks | |
Secondary | 6/12-week abdominal pain response | 6/12-week abdominal pain response: defined as achieving the weekly abdominal pain response for =6 out of the 12 weeks of the RTP | 12 weeks | |
Secondary | Change from baseline in average weekly SBM frequency | Change from baseline in average weekly SBM frequency | 12 weeks | |
Secondary | Change from baseline in average weekly stool consistency score | Change from baseline in average weekly stool consistency score | 12 weeks | |
Secondary | Change from baseline in average weekly abdominal pain score | Change from baseline in average weekly abdominal pain score | 12 weeks | |
Secondary | Overall use of rescue medication | Overall use of rescue medication | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02316899 -
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT02493036 -
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
|
Phase 2 | |
Completed |
NCT03471728 -
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
|
||
Recruiting |
NCT05240521 -
Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C
|
N/A | |
Completed |
NCT02495623 -
A Study of the Effect of SYN-010 on Subjects With IBS-C
|
Phase 2 | |
Completed |
NCT01880424 -
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
|
Phase 3 | |
Completed |
NCT02078323 -
Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
|
N/A | |
Enrolling by invitation |
NCT05905926 -
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
|
Phase 3 |